Doctors often use a blood test called prostate-specific antigen, or PSA, to follow prostate cancer. When treatment works, PSA ...

Add Yahoo as a preferred source to see more of our stories on Google. b' Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023 ...

Among patients with metastatic or very high-risk nonmetastatic prostate cancer, lower prostate-specific antigen (PSA) levels during hormone-based therapy — particularly ≤ 0.2 ng/mL — were strongly ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

A real-world analysis suggests that achieving a prostate-specific antigen (PSA) level < 0.2 ng/mL within 9 months of starting androgen deprivation therapy (ADT)-based treatments was the PSA benchmark ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

Prostate-specific antigen (PSA) is a protein made by the prostate gland. A high PSA level could be a sign of an enlarged prostate, inflammation called prostatitis, or prostate cancer. The PSA test ...

A prostate-specific antigen (PSA) test is a blood test that measures a protein released in the blood by prostate cells. Both normal and cancerous prostate cells release the protein. Most of the time, ...